Imaging scan to see how well breast cancer responds to T-DXd
Part of Cancer, Skin clinical trials.
This study tests whether a special imaging scan can help doctors see how well breast cancer responds to a drug called T-DXd. You will get the imaging agent before your usual T-DXd treatment, and the scan will show if the drug is reaching the tumors.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have advanced or metastatic breast cancer and are scheduled to receive a drug called T-DXd (trastuzumab deruxtecan) as part of your standard care.
- You have not received T-DXd before.
- You have at least two tumor spots that are at least 1.5 centimeters (about half an inch) across and can be seen on scans.
- You must be able to lie still for 30 minutes and not be claustrophobic.
- You are not pregnant, breastfeeding, or planning to become pregnant during the study or for 90 days after the last study treatment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study is testing whether a special PET scan (HER2-PET) can help predict how well the drug T-DXd (also known as Enhertu) might work for your breast cancer. T-DXd is a targeted therapy that delivers chemotherapy directly to cancer cells with certain markers. The trial will check if the scan can identify which patients are more likely to benefit, which could help personalize treatment.
This study looks at how well a drug called trastuzumab deruxtecan works in people with HER2-low breast cancer that has spread to other parts of the body. It uses PET-CT scans to check the tumor's response to treatment.
This study is testing a drug called T-DXd (a targeted therapy) in people with advanced breast cancer that has HER2 overexpression or underexpression. It looks at how well the drug works in real-world settings, which may provide a new treatment option if your cancer has progressed.
This study tests a drug called T-DXd (trastuzumab deruxtecan) for people with advanced breast cancer that has very low levels of HER2 (a protein that helps cancer grow) and that is also hormone receptor positive. The goal is to see if this drug can help shrink or slow the cancer.
This trial studies how the drug T-DXd (trastuzumab-deruxtecan) works in people with advanced or metastatic breast cancer. It compares drug levels in the body based on body mass index (BMI) to see if dose adjustments are needed.
This trial uses a special PET/CT scan to find breast cancer cells that have a certain marker (CD73). It may help doctors see the cancer more clearly before you start other treatments.
Hear when a new Locally Advanced or Metastatic Breast Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.